NCT07895563Active, not recruiting
A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite Control
Source: ClinicalTrials.gov · Last updated 26 Oct 2026
Brief summary (registry, in English)
This is a randomized, double-blind, placebo-controlled, decentralized clinical trial evaluating the effects of MN Nutra GeLiPthin-1™, a multi-ingredient dietary supplement, on body weight, BMI, waist circumference, appetite, satiety, and energy levels in overweight and obese adults over six weeks. A total of 170 generally healthy adults aged 18-65 years with a BMI of 27.0-35.0 kg/m² will be randomized 1:1 to receive either the active supplement or a matching placebo. Participants will take three capsules orally twice daily for six weeks. All study activities are conducted remotely, including electronic consent, self-administered anthropometric measurements using a sponsor-provided Withings Scale and tape measure, and weekly online questionnaires via the Citruslabs digital study platform. The primary outcome is change in body weight from Baseline to Week 6.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 170 (estimated)
- First submitted
- 19 Oct 2026
- Start date
- 27 Aug 2026
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- MNnutra
- Diseases
- Obesity
- NCT number
- NCT07895563
What you commit to
- Study type: Interventional
- Planned participants: 170
- From 27 Aug 2026 to the primary completion date, 31 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current use or use within three months of GLP-1 receptor agonists (e.g., semaglutide/Ozempic/Wegovy, liraglutide/Saxenda/Victoza, tirzepatide/Mounjaro/Zepbound, or dulaglutide/Trulicity) or any prescription weight-loss medication.
- Concurrent use of overlapping weight-management dietary supplements that participants are unwilling to discontinue for the study duration.
- Heavy drinkers or drug users.
Other illness
- Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
- Anyone who is currently undergoing treatment for cancer, or has had a serious illness requiring hospitalization in the last 3 months.
- Currently enrolled in a medically supervised weight-loss program, or has a history of bariatric surgery within the past 12 months.
- Active or historical eating disorder (e.g., anorexia nervosa, bulimia nervosa, binge eating disorder).
- Known allergy or hypersensitivity to any ingredient in the study product or placebo.
- Diagnosed diabetes (type 1 or type 2) or use of insulin or antidiabetic medications (e.g., metformin).
- Known cardiovascular disease or uncontrolled hypertension.
- Clinically significant liver disease or known abnormal liver function.
Other
- Currently undergoing or planning to undergo any significant medical procedures in the next six weeks.
- Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period).
- A heavy drinker is considered to be a woman who drinks 8 or more alcoholic drinks per week or a man who drinks 15 or more alcoholic drinks per week.
- Currently testing, or planning to in the next six weeks, a product for another research study.
Who the study is looking for
- Male or female.
- Aged 18 to 65 years.
- Anyone currently experiencing issues regarding all of the following: healthy weight management
- appetite management and/or food cravings
- energy levels.
- Resides in the United States.
- Body Mass Index (BMI) ≥ 27.0 and \< 35.0 kg/m².
- Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
- Willing to follow the study protocol.
- Willing to maintain current diet, physical activity, and lifestyle habits for the study duration.
- Willing to abstain from alcohol consumption during the study period.
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Citruslabs Coordinator of this site? Confirm its status | Las Vegas | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.